Why the study?
Does the novel renin inhibitor KRI-1314 reduce blood pressure and plasma renin activity in preclinical models?
Does the novel renin inhibitor KRI-1314 reduce blood pressure and plasma renin activity in preclinical models?
KRI-1314 is a potent, orally effective renin inhibitor that lowers blood pressure in preclinical models, suggesting potential as a novel antihypertensive agent.
Answers are grounded in this paper and cite their sources.
Does not support clinical use; extends preclinical evidence for oral renin inhibition but leaves translation open.
In our continuing search for low molecular weight, human renin inhibitors, a dipeptide derivative, morpholino-naphthyl-acyl-histidyl-cyclohexyl-norstatine (KRI-1314), was newly synthesized and estimated for oral effectiveness. This compound inhibited plasma renin from humans and from Japanese monkeys in vitro, with 50% inhibitory concentrations (IC50) of 4.7 x 10(-9) and 2.4 x 10(-8) mol/l, respectively. The mean blood pressure of sodium-depleted Japanese monkeys was lowered significantly after intravenous injection or oral administration of KRI-1314. The maximum reduction was attained 3 h after oral administration at a dose of 10 mg/kg. Plasma renin activity (PRA) was halved 1 h after oral administration of KRI-1314, and this inhibition persisted for more than 5 h. results suggest that KRI-1314, a potent, orally effective and long-lasting renin inhibitor, may become one of a new class of antihypertensive agent.
No takes yet. Share an insight, caveat, or question.
Miyazaki et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: